Month: August 2025

WAMCO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Western Asset Management Company, LLC Mutual Fund Investors with Losses in Excess of $100K to Secure Counsel Before Important September 5 Deadline in Securities Class Action

by

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the “Western Asset US Core Bond Fund” mutual fund classes – Class I (ticker: “WATFX”), Class A (ticker: “WABAX”), Class C (ticker: “WABCX”), Class FI (ticker: “WAPIX”), Class IS (ticker: “WACSX”), and Class R (ticker: … Read more

CAPR DEADLINE: ROSEN, A TRUSTED INVESTOR RIGHTS FIRM, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CAPR

by

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”), of the important September 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased … Read more

Sarborg Limited Closes $10 Million Seed Round to Expand Proprietary Agentic Approach

by

Funding supports next-generation AI agent development and proprietary Intellectual Property, focused initially on pharmaceutical drug-repurposing Initial clients reporting commercial success, revolutionizing indication selection of lead programs Early commercial success and key partnerships signal strong market traction and scalability potential into multiple commercial verticals WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) — Sarborg Limited (“Sarborg” or … Read more

Sarborg Limited Closes $10 Million Seed Round to Expand Proprietary Agentic Approach

by

Funding supports next-generation AI agent development and proprietary Intellectual Property, focused initially on pharmaceutical drug-repurposing Initial clients reporting commercial success, revolutionizing indication selection of lead programs Early commercial success and key partnerships signal strong market traction and scalability potential into multiple commercial verticals WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) — Sarborg Limited (“Sarborg” or … Read more

Sarborg Limited Closes $10 Million Seed Round to Expand Proprietary Agentic Approach

by

Funding supports next-generation AI agent development and proprietary Intellectual Property, focused initially on pharmaceutical drug-repurposing Initial clients reporting commercial success, revolutionizing indication selection of lead programs Early commercial success and key partnerships signal strong market traction and scalability potential into multiple commercial verticals WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) — Sarborg Limited (“Sarborg” or … Read more

Sarborg Limited Closes $10 Million Seed Round to Expand Proprietary Agentic Approach

by

Funding supports next-generation AI agent development and proprietary Intellectual Property, focused initially on pharmaceutical drug-repurposing Initial clients reporting commercial success, revolutionizing indication selection of lead programs Early commercial success and key partnerships signal strong market traction and scalability potential into multiple commercial verticals WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) — Sarborg Limited (“Sarborg” or … Read more

Sarborg Limited Closes $10 Million Seed Round to Expand Proprietary Agentic Approach

by

Funding supports next-generation AI agent development and proprietary Intellectual Property, focused initially on pharmaceutical drug-repurposing Initial clients reporting commercial success, revolutionizing indication selection of lead programs Early commercial success and key partnerships signal strong market traction and scalability potential into multiple commercial verticals WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) — Sarborg Limited (“Sarborg” or … Read more

Sarborg Limited Closes $10 Million Seed Round to Expand Proprietary Agentic Approach

by

Funding supports next-generation AI agent development and proprietary Intellectual Property, focused initially on pharmaceutical drug-repurposing Initial clients reporting commercial success, revolutionizing indication selection of lead programs Early commercial success and key partnerships signal strong market traction and scalability potential into multiple commercial verticals WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) — Sarborg Limited (“Sarborg” or … Read more